Company intelligence / Profile preview

Shenzhen KYD Biomedical Technology

Shenzhen, Guangdong, Chinasalubris.com ↗

Ownership: Private
Development stage: Other

Overview

Shenzhen KYD Biomedical Technology has developed at least two innovative medical devices that have completed multicenter randomized controlled clinical trials. The SaExten Vena Cava Filter System was shown to be effective and safe for preventing pulmonary embolism, while the LAMax Left Atrial Appendage Closure System was evaluated for reducing stroke risk in patients with non-valvular atrial fibrillation[1].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Second Affiliated Hospital Zhejiang University School of Medicine

Beyond the preview

Go deeper on Shenzhen KYD Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen KYD Biomedical Technology.

Explore the full profile